Allogeneic stem cell transplantation in multiple myeloma after standard myeloablative conditioning induces a high rate of complete remissions, but long-term freedom from disease is achieved in 30-40% of the cases only. The therapeutic effect of allogeneic stem cell transplantation is due to cytotoxicity of high-dose chemotherapy and immune-mediated graft-versusmyeloma effect by donor T cells. Retrospective studies clearly suggest that both (a) reducing the intensity of high-dose chemotherapy by using reduced-intensity or non-myeloablative conditioning regimen or (b) reducing the immunotherapy of donor T cells by using T-cell depletion result in lower treatmentrelated morbidity and mortality, but also in higher rate of relapse. Therefore, this review will focus on potential strategies of how treatment-related morbidity and mortality might be kept low without an increased risk of relapse and how remission status after transplantation can be enhanced by using the newly established donor immunosystems after allografting as a platform for post-transplant treatment strategies with new drugs (thalidomide, lenalidomide, bortezomib) or immunotherapy (donor lymphocyte infusion, vaccination, tumor-specific T cells) in order to achieve remission on a molecular level, which seems to be a 'conditio sine qua non' to cure myeloma patients.
Introduction
Compared with other treatment modalities in multiple myeloma, allogeneic stem cell transplantation induces the highest rate of clinical complete remission (CR) and molecular remission, 1, 2 resulting in long-term freedom from disease in about 30-40% of the cases. [3] [4] [5] [6] [7] However, despite the recent improvement in performing allogeneic stem cell procedure, 8 it is the treatment modality with the highest treatment-related morbidity and mortality. Both morbidity and mortality are due to organ toxicity induced by the conditioning regimen and immunological complications after transplantation such as graft-versus-host disease (GvHD) and infectious diseases.
From the view of clinical efficacy, allogeneic stem cell transplantation consists of two different therapeutic approaches, each capable of inducing marked cytotoxicity in myeloma patients: (1) high-dose chemotherapy and (2) immunotherapy mediated by immunocompetent donor T cells.
High-dose chemotherapy alone (supported by autologous stem cell transplantation) has become the standard treatment of patients up to the age of 65 years, but the long-term results are not satisfying because ultimately all patients will relapse, suggesting that chemotherapy given at its maximal tolerable dose is unlikely to eradicate all myeloma cells. 9, 10 Evidence of a strong immunologically mediated anti-myeloma effect came from donor lymphocyte infusions (DLIs) given to patients who relapsed after allogeneic stem cell transplantation. Response rate (CR/partial remission (PR)) between 40 and 67% can be achieved, but these remissions are durable only in a minority of patients. 11, 12 Therefore, the existing 'graft-versus-myeloma' effect is less potent than in other diseases such as chronic myeloid leukemia or chronic lymphocyte leukemia, suggesting that immunocompetent donor T cells alone are unlikely to be successful in eliminating all myeloma cells in patients with multiple myeloma. Despite the high efficacy of high-dose chemotherapy as well as of immunotherapy by immunocompetent donor T cells, each therapeutic approach alone seems to be insufficient to induce long-term freedom from disease, but the combination of both (Dallogeneic stem cell transplantation after standard conditioning regimen) induces long-term freedom from disease in about 30-40% of the patients. Despite the curative potential, the major concern of allogeneic stem cell transplantation lies in the treatment-related mortality (TRM), as well as in high risk of relapse. Therefore, this spotlight will not give an extended review of the still growing literature on allogeneic stem cell transplantation in myeloma, but mainly focus on the aforementioned two sides of the coin and how both can be improved by reducing TRM as well as relapse rate to achieve an ultimate cure for myeloma patients.
Lowering treatment-related mortality Reducing regimen-related toxicity. Murine studies showed that leukemia-bearing recipients had better survival after allogeneic than after syngeneic transplantation, 13 and Mathe 14 described this phenomenon in 1965 as 'adoptive immunotherapy'. These early studies provided evidence that curing hematological diseases is not related to high-dose conditioning regimen alone. As the toxicity of the conditioning regimen before allogeneic stem cell transplantation contributes to treatment-related morbidity and TRM, a strategy to reduce TRM might be to minimize the toxicity of myeloablative standard conditioning. This approach provided ensured allogeneic engraftment and shifted tumor reduction from the preparative regimen to immunocompetent donor cells by inducing a graft-versus-myeloma effect. Because of its low intensity, such regimens were called 'non-myeloablative', but several regimens are still myeloablative and claimed 'RIC' or 'toxicity-reduced' conditioning. The most commonly used regimens in myeloma are either a very-low-intensity approach using 2 Gy total-body irradiation (TBI) with or without fludarabine, or melphalan at an intermediate dose of 100-160 mg/m 2 in combination with fludarabine [15] [16] [17] [18] 19 or busulfan 20 in combination with fludarabine have also been investigated. In Table 1 , selected studies on patients with advanced multiple myeloma using different intensities of the conditioning regimen and their effect on outcome are listed. [21] [22] [23] [24] Taking into account the heterogeneous course of the disease, the selection bias, the different GvHD prophylaxes and other prognostic factors, these data suggest a positive correlation between higher CR rate as well as higher TRM and the intensity of the conditioning regimen. This is in accordance with a recently performed retrospective comparison from the European Group for Blood and Marrow Transplantation (EBMT), which reports a higher CR rate for myeloablative conditioning in comparison to reduced-intensity conditioning (RIC) (53 vs 34%, Po0.001). 25 The results given in Table 1 for those using standard myeloablative conditioning also suggest for an improvement in time, especially with respect to TRM. The Myeloma Subcommittee of the EBMT reported a better survival for myeloma patients transplanted after 1994 in comparison to those who received an allograft before 1994 (overall survival at 3 years: 56 vs 35%). 8 This major improvement is due to a marked reduction in TRM (30 vs 46%), probably owing to better patient selection and improved supportive care. More recently, smaller Phase II studies using myeloablative conditioning reported TRM rates of less than 20% suggesting only marginal difference in TRM between myeloablative and RIC. [5] [6] [7] However, the median age of the patients treated with standard conditioning was about 10 years younger in comparison to those treated with RIC. The above-mentioned study of the Myeloma Subcommittee of the EBMT comparing a RIC (n ¼ 320) with myeloablative conditioning (n ¼ 196) showed a reduced nonrelapse mortality for RIC transplantation (24 vs 37%, P ¼ 0.002), but a lower progression-free survival (19 vs 35%, P ¼ 0.001) and no statistical difference in overall survival (38 vs 51%, NS). On multivariate analysis, RIC was associated with lower non-relapse mortality (HR: 0.5), but a higher risk of relapse (HR: 2.0). 25 Besides the influence of the intensity of the conditioning regimen, there is also increasing evidence that the timing of RIC transplantation is crucial for lowering TRM (Figure 1) . Patients who underwent RIC transplantation after failure of previous autograft have a higher risk of relapse and of non-relapse mortality than those patients without relapse to an autograft. 24 A worse event-free and overall survival has also been reported for patients with chemorefractory disease and reduced performance status. 26 A further risk for survival in myeloma patients is cytogenetic abnormalities. 27, 28 For allogeneic stem cell transplantation, only deletion 13q14 has been investigated and shown to be associated with worse outcome. 29 Other abnormalities such as t(4;14) and del(17p), which were the most significant abnormalities after autologous stem cell transplantation, 27, 28 have not yet been investigated for allogeneic stem cell transplantation. Table 1 CR, TRM and survival of different conditioning regimens in advanced multiple myeloma patients (excluding planned auto-allo)
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Abbreviations: CR, complete remission; TRM, treatment-related mortality. a Different regimens, mainly total body irradiation/cyclophosphamide or busulfan/cyclophosphamide. Figure 1 Cumulative incidence of treatment-related mortality (TRM) and relapse after dose-reduced conditioning in patients with (right) and without (left) failure to a prior autograft (modified and adapted from Krö ger N et al.
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Overall, the available data suggest that reducing the intensity of the conditioning regimen lowers the treatment-related toxicity and TRM, but increases the risk of relapse.
Combining autologous and allogeneic stem cell transplantation. As low-intensity conditioning approach, which is mainly focused on immunocompetent donor T cells, is not sufficient to control advanced disease in myeloma patients, 21, 30 it became clear that further effective cytoreductive treatment might be appropriate. To maintain the two treatment approaches of allogeneic stem cell transplantation, namely high-dose chemotherapy and adoptive immunotherapy with a lower TRM, the concept of autologous-allogeneic-tandem transplantation was introduced. 15, 16, 31 In this treatment concept, high-dose chemotherapy and adoptive immunotherapy by immunocompetent donor T cells were splitted within an interval of 2-3 months in order to lower toxicity and TRM, but to maintain high-dose chemotherapy as well as the immuno-mediated graftversus-myeloma effect. Table 2 shows the results of six studies investigating a dose-reduced allograft after a cytoreductive autograft 15, 16, [31] [32] [33] (Seok L et al. Blood 2003; 102: Abstract 5593). In contrast to transplantation without preceding cytoreduction (see Table 1 ), there seems to be no difference regarding CR and transplant-related mortality between the different intensities of the conditioning regimens (2 Gy TBI vs intermediate dose of melphalan). Only the busulfan (4 mg/kg BW)/ fludarabine regimen of the randomized IFM99 protocol resulted in a lower CR rate and a worse 2-year overall survival. This could be due to the very-high-risk group of patients included or, more likely, due to the use of high-dose anti-thymocyte globulin (12.5 mg/kg Thymoglobulin), which might have offset the graftversus-myeloma effect by profound T-cell depletion. This randomized study did not show any significant difference in event-free and overall survival between the auto-allo-and the tandem-auto-arm after a median follow-up of 24 months. 33 More recently, the Italian study group compared 80 patients with multiple myeloma who had an human leukocyte antigen (HLA)-identical sibling and were planned to receive auto-allotandem transplantation with 82 patients without HLA-identical sibling who were planned to receive tandem-autologous stem cell transplantation. 32 The median overall survival and eventfree survival were longer in patients with HLA-identical siblings than in those without an HLA-identical sibling (80 vs 54 months, P ¼ 0.01 and 35 months vs 29 months, P ¼ 0.02, respectively). Among those who completed the assigned treatment (tandem autologous: n ¼ 46; autologous-allogeneic: n ¼ 58), the diseaserelated mortality was significantly higher in the tandemautologous-transplant group (43 vs 7%, Po0.001). As the medium survival of the tandem-autologous group was rather short (54 months) and only 56% of the planned auto-allo group completed the assigned treatment, a selection bias cannot be excluded. Other prospective randomized studies comparing tandem-autologous transplantation with auto-allo transplantation are either ongoing (Bone Marrow Transplant Clinical Trial Network (BMT/CTN)) or have completed accrual (EBMT-trial NMAM2000) but not yet presented data.
Overall, the auto-allo-tandem approach seems to result in a similar outcome as standard myeloablative allografting, but with lower TRM.
Reducing GvHD-related mortality. Besides the toxicity of the conditioning regimen, GvHD and associated infectious complications remain a major cause of treatment-related morbidity and mortality. A lower intensity of the conditioning regimen reduced organ toxicity and to a lesser extent GvHD. The incidence of acute GvHD is lower after RIC transplantation in comparison to standard conditioning, although the incidence of chronic GvHD is similar. 34, 35 Already in 1979 and 1981, it could be shown that patients who developed acute or chronic GvHD were less likely to develop leukemic relapse. 36, 37 The most effective strategy to avoid GvHD and GvHD-associated mortality is T-cell depletion of the graft, which, however, is associated with a profound risk of relapse. The importance of chronic GvHD on the risk of relapse after RIC and allografting in myeloma patients has been shown by several investigators. 15, 19, 26, 35, 38 Therefore, one should be aware that T-cell depletion in multiple myeloma might increase the risk of relapse. As the major aim of RIC transplantation is shifting the tumor reduction from the preparative regimen to immunocompetent donor cells, it is surprising that in Europe more T-celldepleting strategies in myeloma patients were used in RIC than in myeloablative transplantation: only 37% of 320 RIC transplantations were performed without any T-cell depletion, whereas after myeloablative conditioning, 42% of 196 patients were transplanted without any T-cell depletion. 25 T-cell depletion with alemtuzumab, an anti-CD52 monoclonal antibody, was an independent significant risk factor for relapse (HR: 2.3), progression-free (HR: 1.8) and overall survival (HR: 1.8) for RIC transplantation in a retrospective EBMT study. 25 All other forms of T-cell depletion were only associated with a higher risk of relapse (HR: 1.6). Other common forms of T-cell depletion are anti-thymocyte globulins (ATGs) as part of the conditioning regimen. ATG is a polyclonal anti-human T-cell globulin derived from rabbit or horse after vaccination from human thymocyte or T-cells. Most of the centers used antihuman globulins from rabbit. ATG derived from vaccinations with human thymocyte (Thymoglobulin, Genzyme (Cambridge, MA, USA)) should be distinguished from preparations derived from human Jurkat T-cell line (anti-lymphocyte globulin, ATGFresenius). Both globulins have different immunological properties and are given in different doses. Thymoglobulin has broader activity on T-cell depletion, whereas ATG-Fresenius mainly Table 2 Allogeneic reduced-intensity conditioning after prior cytoreductive autograft (auto-allo approach) 39, 40 More recently, ATG preparations as polyclonal antibody have shown in vitro complement-dependent and apoptosis-mediated cytotoxicity on myeloma cells. 41, 42 Therefore, ATG might be able to improve remission rate after transplantation. However, the role of ATG in allogeneic stem cell transplantation of myeloma patients needs to be determined. In a retrospective comparative study between ATG and alemtuzumab in multiple myeloma and related stem cell transplantation, ATG was associated with a significantly higher rate of CR. In contrast, alemtuzumab resulted in lower incidence of GvHD, but higher incidence of relapse than in the ATG group. 43 Even if ATG has anti-myeloma activity, its use should be carefully balanced against the potential loss of the graft-versus-myeloma effect. In this line, the high relapse incidence of the allo-RIC-arm in the randomized IFM99 study is at least in part caused by the high dose of Thymoglobulin (12.5 mg/kg BW).
Overall, the stronger the T-cell depletion strategies, the lower the GvHD incidence, but the higher the relapse risk.
Reducing the risk of relapse Improving pretransplant disease status. In general, before autologous or allogeneic stem cell transplantation, several cycles of induction chemotherapy were performed to lower the tumor burden. However, the regimens used in the past such as VAD (vincristine/adriamycin/dexamethasone) or ID (idarubicin/dexamethasone) induce CR rates in less than 10%. Since its introduction in the 1980s, 44 VAD became the most commonly used regimen for myeloma patients before autologous stem cell transplantation. Since the availability of new drugs such as bortezomib, thalidomide or lenalidomide, with new combination therapies such as thalidomide/dexamethasone, bortezomib/dexamethasone or bortezomib/thalidomide/ dexamethasone, CR rates of about 20% can be achieved in newly diagnosed patients 45, 46 (Wang M et al. Blood 2005; 106: Abstract 784). This better remission status before autologous or allogeneic stem cell transplantation might result in lower relapse rate after transplantation; however, results from ongoing studies are premature to come to any conclusion.
Targeting molecular remission. CR in patients with multiple myeloma is defined by negative immunofixation. Several investigators have showed the importance of achieving CR on the duration of event-free survival after autologous stem cell transplantation. 47 However, the sensitivity of immunofixation to detect residual disease is low. As residual disease is associated with relapse risk, more sensitive methods to detect residual disease in myeloma patients have been investigated. The most sensitive method is based on clonal markers derived from the rearrangement of immunoglobulin heavy-chain genes, which have to be generated from each patient at diagnosis. Using these patient-specific primers, residual myeloma cells can be detected by polymerase chain reaction (PCR) with a sensitivity of 10 À4 -10 À6 .
1,2
Molecular remissions are seen more often after allogeneic than after autologous stem cell transplantation. In patients who achieved clinical CR, 9 out of 14 were allograft patients, but only 2 out of 15 autograft patients entered molecular remission. It is of interest that molecular remission after allografting occurred in some patients more than 3 years after transplantation. 1 The importance of achieving molecular remission for longterm disease freedom has been shown for myeloablative allogeneic stem cell transplantation in a retrospective EBMT study. 48 In this study, using highly sensitive patient-specific primers to monitor residual disease with PCR technique, it could be shown that durable PCR-negativity after allografting had a cumulative risk of relapse at 5 years of 0%, in comparison to 33% for PCR-mixed patients and 100% for patients who never achieved PCR-negativity. The disadvantages of using patientspecific primers to detect minimal residual disease are the costs and the time-consuming procedure. Alternatively, interphase fluorescence in situ hybridization allows detection of residual plasma cells at a lower sensitivity if cytogenetic markers (for example, del(13q14)) are available. 49 A high sensitivity can be achieved by using plasma cell chimerism with real-time PCR based on sequence polymorphisms. 50 The drawbacks of the method are the low specificity and its assessment only after allografting.
These results suggest that achieving molecular remission is required for long-term freedom from disease and curing myeloma. Preliminary results from our study group and other investigators showed that by using nested PCR or real-time PCR, molecular remission can be achieved after dose-reduced allograft, and quantitative measurement of residual myeloma cells can be used for further post-transplant strategies in order to achieve molecular remission 51 Targeting molecular remission also implies the recently discovered myeloma stem cells, a rare population of cells that maintain the ability to self-renew and sustain tumor. 52 Antimyeloma agents such as bortezomib or lenalidomide have little activity against myeloma stem cells in vitro, whereas rituximab kills myeloma stem cells in vitro. 52 So far, only limited efficacy has been reported for rituximab in the treatment of multiple myeloma. 53, 54 Overall, to cure patients with multiple myeloma, achievement of molecular remission seems to be a 'conditio sine qua non'.
Post-transplant strategies. Despite the high rate of CRs achieved after auto-allo-tandem transplantation (see Table 2 ), the relapse rate is considerable, exceeding nearly 50% in 3 years. The importance of molecular remission on long-term freedom of disease has been mentioned above. Therefore, posttransplant strategies either as maintenance therapy or to improve remission status are of clinical importance. After autologous stem cell transplantation, therapy with thalidomide given as maintenance therapy resulted in an improved event-free and overall survival. 55 Despite the high risk of relapse after allografting, there are only few reports in the literature about post-transplant strategies after allogeneic stem cell transplantation in multiple myeloma. The commonly used adoptive immunotherapy after allogeneic stem cell transplantation is DLI. 56 In multiple myeloma, in most reports, DLI was given for relapse, 11, 12, [57] [58] [59] [60] and only few reported about prophylactic DLI. [61] [62] [63] Response rates between 40 and 67% were reported, but in some studies, additional chemotherapy or interferon-a was given. 11, 12 Nearly 30% of the patients achieved CR, and response to DLI was correlated for occurrence and severity of acute GvHD. The incidence of acute GvHD ranges between 52 and 56%, and of chronic GvHD between 26 and 44%. 11, 12 DLI given after RIC in a dose-escalating way resulted in less acute and chronic GvHD. 60, 62 In a European survey, the effect of DLI after RIC was investigated in patients with relapse (n ¼ 48) or persistent 64 The median time to progression was 7 months for patients achieving PR and 28 months for patients achieving CR. To reduce the risk of GvHD after DLI, CD8-depleted DLIs were investigated in 14 patients in CR (n ¼ 3) or persistent disease (n ¼ 11) after allogeneic bone marrow transplantation. Six out of the 10 patients with measurable disease experienced CR. Acute GvHD (grade II-IV) was seen in 50% of the patients. 61 To enhance the anti-myeloma effect of DLI after allografting, low-dose thalidomide (100 mg) in combination with DLI was investigated. The overall response rate was 67% with 22% CR. Interestingly, no grade II-IV acute GvHD was seen, and only a small minority developed limited chronic GvHD. 65 Other new drugs such as the proteasomeinhibitor bortezomib might have a major role after allogeneic stem cell transplantation because it could be shown in preclinical mice models that proteasome inhibition inhibits T-cell proliferation and acute GvHD with the graft-versus-tumor Table 3 Post-transplant strategies to enhance remission status or to treat relapse . Interferon-a alone induces a CR without GvHD in four out of five patients after allograft, but because interferon-a was given rather early at a median of 126 days after transplantation, the contribution of interferon to achieve CR remains unclear. 71 The major issue for further improvement of immunologically based strategies post-allo-transplant lies in the separation of the graft-versus-myeloma effect from the graft-versus-host reaction, which would allow a more specific tumor targeting without or with lesser risk of GvHD. Potential candidates for a more specific T-cell response are minor histocompatibility antigens such as HA-1. More recently, HA-1-specific T-cells could be generated and induced CR in a patient with relapsed multiple myeloma after allogeneic stem cell transplantation. 72 A potential target for tumor-specific donor T-cell response is the myeloma-specific idiotypic determinant of immunoglobulinvariable region, which has been used to immunize the donor before the allogeneic stem cell transplantation in order to transplant a myeloma-specific T-cell response. 73 Two out of five patients remained disease-free after allografting for 7 and 8 years, respectively, although one patient died of renal failure 5 years after transplantation. In all patients, immunoglobulinspecific T-cell response was seen and persisted for 18 months 74 (also see Table 3 ). Another potential target is cancer-testis (CT) antigens, especially MAGEC2 or MAGEA3, which are expressed in more than 55% of myeloma cells. 75 A donor vaccination with MAGEA3 induced T-cell response in the donor as well as in the recipient after stem cell transplantation (Gnjatic S et al. Blood 2005, 106: Abstract 620A 2197). However, frequent antibody response against CT antigen was observed after allografting without donor vaccination. 75 This antibody response correlated with specific CD4 þ and CD8 þ T-cell response. This response was not detectable in pretransplantation samples neither in the patients nor in the donor, suggesting that CT antigens might represent natural target for graft-versus-myeloma effect. More recently, killer-immunoglobulin-like-receptor-ligand-donor/ recipient-mismatch transplantation may be protective against relapse, suggesting a potential role of alloreactive NK-cells after allografting to enhance remission status and prevent relapse. 43 
Conclusion
The available data on intensity of pretransplant conditioning regimens suggest that reducing the intensity resulted in lower non-relapse mortality, but higher risk of relapse. Retrospective comparison suggests that combination of autologous transplantation with a dose-reduced allograft induces similar results in remission rates, but lower non-relapse mortality than standard myeloablative allografting. The target for achieving cure from myeloma is molecular remission. Therefore, post-transplant strategies are mandatory in order to achieve molecular remission. The new donor immunosystem after allografting offers a platform for numerous drug-based or immunologically based post-transplant therapies. Figure 2 shows a possible scenario for treating patients with multiple myeloma to obtain molecular remission, which seems to be a 'conditio sine qua non' for curing the disease.
